Genetic evidence supporting a causal role of Janus kinase 2 in prostate cancer: a Mendelian randomization study

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Janus kinase-2 (JAK2) inhibitors are increasingly used in prostate cancer (PCa) research and treatment.
• The precise causal link between JAK2 and PCa remains unclear.
• This study investigates the cause-effect relationship between JAK2 and PCa.

Purpose of the Study:

• To examine the causal relationship between Janus kinase-2 (JAK2) and prostate cancer (PCa).
• To determine if JAK2 acts as a risk factor in PCa development.
• To provide insights into the clinical application of JAK2 inhibitors for PCa.

Main Methods:

• Utilized a two-sample Mendelian randomization (MR) analysis.
• Employed genetic variation data for JAK2 and PCa from the IEU OpenGWAS Project.
• Applied inverse variance weighted, MR-Egger, and weighted median methods, with sensitivity analyses including Cochran's Q test and MR-Egger intercept analysis to ensure result validity.

Main Results:

• Identified five instrumental variables for the MR analysis.
• Inverse variance-weighted and weighted median analyses indicated a significant association between JAK2 and PCa (ORs approx. 1.0009, p < 0.05).
• Sensitivity analyses confirmed no significant heterogeneity or horizontal multiplicity among the instrumental variables (p > 0.05).

Conclusions:

• Janus kinase-2 (JAK2) is significantly associated with the development of prostate cancer (PCa).
• JAK2 is confirmed as a risk factor for PCa.
• These findings may guide the therapeutic use of JAK2 inhibitors in PCa management.